The US Food and Drug Administration (FDA) has approved revised labeling for 3 estradiol transdermal patches used in menopausal hormone therapy, removing warnings about cardiovascular disease, breast cancer, and probable dementia from their boxed warnings, according to an October 30 press release from the US Department of Health and Human Services (HHS). The changes affect estradiol products marketed as Minivelle, Vivelle, and Vivelle-Dot but do not eliminate the underlying risks associated with systemic hormone therapy.
The October 30 decision follows the FDA's February approval of similar labeling revisions for 6 menopausal hormone therapy products, according to HHS. Although warnings about cardiovascular disease and breast cancer have been removed from the boxed warning section, information about these risks remains elsewhere in the prescribing information. The boxed warning for endometrial cancer associated with unopposed systemic estrogen therapy in women with a uterus also remains. The revised Vivelle-Dot label continues to list current or prior breast cancer, deep vein thrombosis, pulmonary embolism, and arterial thromboembolic disease among its contraindications, and recommends evaluating vascular and thromboembolic risk factors before treatment.
The FDA has questioned how broadly findings from the Women's Health Initiative (WHI) trials, which informed earlier hormone therapy warnings, apply to women beginning treatment closer to menopause. Participants in the original WHI hormone trials had an average age of 63 years, whereas menopausal symptoms commonly begin earlier. The agency's updated labeling approach emphasizestreatment timing, with the revised Vivelle-Dot prescribing information advising clinicians to consider initiating therapy in women younger than 60 years or within 10 years of menopause. The label also notes that the WHI estrogen-alone trial evaluated oral conjugated estrogens and that the applicability of its cardiovascular findings to other estrogen products or routes of administration remains uncertain.
HHS Secretary Robert F. Kennedy Jr. characterized the removal of the risk statements as part of an effort to update menopause treatment information to reflect the FDA's assessment of available evidence. However, the labeling changes do not establish that hormone therapy is free of cardiovascular or cancer risks.
The October 30 HHS announcement also addressed access to estradiol patches amid increased demand. According to the FDA, manufacturers have doubled overall estradiol patch output over the past 12 months through expanded production capacity and additional manufacturing shifts. The agency reported no imminent risk of a nationwide shortage, although localized supply difficulties persist.
Separately, the FDA is working with manufacturers to explore potential over-the-counter availability of vaginal estrogen products, according to the HHS announcement. No such switch has been approved, and any change would require evidence supporting safe and effective use without supervision by a health care professional.
The FDA continues to review proposed labeling revisions from additional manufacturers, with 29 companies having submitted changes to date, according to HHS. The agency advises patients experiencing difficulty obtaining their usual estradiol patches to consult a pharmacist or health care professional about available alternatives, noting that supply may vary by brand, strength, dosing schedule, and location.
Sources:HHS, FDA Minivelle Prescribing Information, FDA Vivelle Prescribing Information, FDA Vielle-Dot Prescribing Information
